SymBio Pharmaceuticals Limited (SYMQY)
OTCMKTS · Delayed Price · Currency is USD
0.5579
0.00 (0.00%)
Feb 11, 2026, 9:30 AM EST

SymBio Pharmaceuticals Cash Flow Statement

Millions JPY. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
-4,776-3,806-1,1952,1062,032
Depreciation & Amortization
--989993.96
Other Amortization
110.28---1.95
Loss (Gain) From Sale of Assets
-131568-0.69
Asset Writedown & Restructuring Costs
109.27----
Stock-Based Compensation
94.71---124.27
Other Operating Activities
73.7627-377-420-1,048
Change in Accounts Receivable
163.484891,17162-1,741
Change in Inventory
-50.0354237-82559.24
Change in Accounts Payable
-169.38-215-356662-595.78
Change in Other Net Operating Assets
-131.46-96-340-813711.88
Operating Cash Flow
-4,576-3,416-1941,614140.04
Operating Cash Flow Growth
---1052.51%-
Capital Expenditures
--19-204-2-25.45
Cash Acquisitions
-0.02----
Sale (Purchase) of Intangibles
-82.47-27-28-45-38.38
Other Investing Activities
6.5743-144--7.01
Investing Cash Flow
-75.92-3-376-47-70.85
Long-Term Debt Issued
2,925----
Long-Term Debt Repaid
-552.5----
Net Debt Issued (Repaid)
2,372----
Issuance of Common Stock
1,2567096816300.9
Repurchase of Common Stock
-0.05---2-68.83
Other Financing Activities
-6.78-1-1-1-4
Financing Cash Flow
3,622708680627-71.92
Foreign Exchange Rate Adjustments
-50.215812521314.21
Miscellaneous Cash Flow Adjustments
---114-
Net Cash Flow
-1,080-2,5532342,42111.48
Free Cash Flow
-4,576-3,435-3981,612114.59
Free Cash Flow Growth
---1306.78%-
Free Cash Flow Margin
-349.91%-140.09%-7.12%16.11%1.39%
Free Cash Flow Per Share
-91.13-76.17-9.9740.702.95
Cash Interest Paid
39.24----
Cash Income Tax Paid
12.6-393543633.8
Levered Free Cash Flow
-2,885-2,055-143.51,542-226.95
Unlevered Free Cash Flow
-2,901-2,055-143.51,542-226.95
Change in Working Capital
-187.39232712-171-1,065
Source: S&P Global Market Intelligence. Standard template. Financial Sources.